Wegovy in Australia: What It Is, What It Costs, and How to Get a Prescription in 2026
TL;DR
Wegovy is a once-weekly semaglutide injection approved by the TGA in Australia for chronic weight management. It is the same active ingredient found in Ozempic, but at a higher dose (2.4 mg vs up to 2 mg) and with a specific TGA indication for weight loss rather than diabetes. Wegovy is not yet on the PBS for weight management, but the PBAC recommended it for PBS listing in January 2026 for patients with established cardiovascular disease and obesity. Price negotiations with Novo Nordisk are ongoing, with a possible listing in late 2026 or early 2027.
Introduction
Wegovy in Australia is one of the most searched weight loss medications in the country right now, with over 14,800 Australians looking for information about it every month. The interest is driven by a combination of strong clinical evidence, growing media coverage of GLP1 medications, and the January 2026 announcement that the PBAC recommended Wegovy for PBS listing. That recommendation was a landmark decision: it marked the first time an Australian government advisory body endorsed subsidizing a GLP1 medication specifically for weight management. But the recommendation came with strict eligibility criteria that excluded most patients seeking weight loss treatment.
This guide explains what Wegovy is, how it differs from Ozempic, what it costs right now in Australia without PBS subsidy, who will qualify when the PBS listing is finalized, and how to get a prescription through a telehealth consultation with an AHPRA-registered doctor.
What Is Wegovy, and How Does It Differ from Ozempic?
Wegovy and Ozempic both contain the same active ingredient, semaglutide, manufactured by Novo Nordisk. The critical difference is dose and indication. Ozempic is dosed at 0.5 mg, 1 mg, or 2 mg weekly and is TGA approved for type 2 diabetes. Wegovy is dosed at 2.4 mg weekly and is TGA-approved specifically for chronic weight management. They are not interchangeable. For a detailed breakdown of how all four GLP1 medications compare, see the Holistica Health guide to comparing Mounjaro, Ozempic, Wegovy, and Rybelsus.
The higher dose of Wegovy produces greater average weight loss than standard Ozempic doses. In the STEP 1 clinical trial (published in The New England Journal of Medicine, 2021), participants taking Wegovy lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. More than 86% of participants lost at least 5% of their body weight, and approximately one-third lost 20% or more.
Wegovy also holds a TGA and FDA-approved indication for cardiovascular risk reduction, based on the SELECT trial (17,604 participants across 41 countries), which demonstrated a 20% reduction in major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death. No other weight management medication currently holds this cardiovascular indication in Australia.
Is Wegovy on PBS in Australia?
Wegovy is not currently listed on the PBS in Australia. The PBAC recommended a listing in November 2025 and the Health Minister endorsed it in January 2026, but price negotiations between the government and Novo Nordisk are still ongoing. A listing could take effect in late 2026 or early 2027 at the earliest, so most patients currently pay the private price.
In November 2025, the PBAC recommended Wegovy for PBS listing. Health Minister Mark Butler endorsed the recommendation in January 2026 and committed to listing the medication. Price negotiations between the Australian Government and Novo Nordisk are ongoing. Based on standard post-PBAC timelines, a PBS listing could be finalized in late 2026 or early 2027.
The recommended PBS eligibility criteria are significantly narrower than the general TGA prescribing criteria. To qualify for the PBS subsidized price, patients would need to meet both conditions: a BMI of 35 or higher (or 32.5 or higher for Asian, Aboriginal, and Torres Strait Islander populations) AND established cardiovascular disease, specifically a prior heart attack, stroke, or symptomatic peripheral arterial disease.
This means most Australians currently using Wegovy for weight management alone would not qualify for PBS subsidy under these initial criteria. However, initial PBS listings often start narrow and expand over time as real-world data on cost effectiveness accumulates.
How Much Does Wegovy Cost in Australia Without PBS?
Without a PBS subsidy, Wegovy is a private prescription medication. Costs vary depending on whether you are in the dose escalation phase (lower doses cost less) or on the maintenance dose.
As a general guide for Australian patients in 2026, titration doses (0.25 mg through 1.7 mg) cost approximately $160 to $220 per month at retail pharmacy pricing. The maintenance dose (2.4 mg) costs approximately $200 to $460 per month, depending on the pharmacy. If Wegovy is eventually PBS listed with the recommended criteria, eligible patients would pay $25 per script (general) or $7.70 (concession card holders).
Pricing varies significantly between pharmacies. It is worth calling several pharmacies in your area, including Chemist Warehouse, Priceline Pharmacy, and Terry White Chemmart, to compare pricing before filling your prescription. A telehealth consultation to assess your eligibility and obtain a prescription is a separate cost from the medication itself. At Holistica Health, an initial weight loss consultation costs $99.
What Does the Clinical Evidence Show About Wegovy for Weight Loss?
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program is the primary evidence base supporting Wegovy. The program enrolled over 15,000 participants across multiple global trials.
STEP 1 (NEJM, 2021): 1,961 adults with obesity or overweight. Average weight loss of 14.9% over 68 weeks at the 2.4 mg dose, compared to 2.4% on placebo. Over 86% lost at least 5% body weight; approximately one third lost 20% or more.
STEP 3 (JAMA, 2021): Participants received intensive behavioral therapy plus Wegovy. Average weight loss was 16.0% at 68 weeks, demonstrating that combining medication with structured lifestyle intervention improves outcomes.
STEP 5 (Nature Medicine, 2022): The two-year extension trial. Participants maintained an average 15.2% weight loss at 104 weeks (two full years), confirming that benefits are sustained with continued treatment.
SELECT (NEJM, 2023): 17,604 adults with established cardiovascular disease and overweight or obesity. Semaglutide 2.4 mg produced a 20% reduction in major adverse cardiovascular events (MACE) over a mean follow-up of 33 months. Weight loss averaged 10.2% at 208 weeks (four years). This trial is the reason Wegovy now holds a cardiovascular risk reduction indication.
For context, tirzepatide (Mounjaro) produced 20.2% average weight loss in the SURMOUNT 5 head-to-head trial, compared to 13.7% for semaglutide. However, Wegovy has the advantage of published cardiovascular outcomes data (SELECT) that tirzepatide does not yet have.
What Are the Common Side Effects of Wegovy?
Wegovy shares the same side effect profile as other GLP1 receptor agonists. The most common adverse effects in clinical trials were gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. These effects are most prevalent during the dose escalation phase and typically diminish as the body adjusts to the medication.
The standard prescribing protocol uses a 16-week dose escalation schedule: starting at 0.25 mg weekly, increasing every four weeks through 0.5 mg, 1 mg, and 1.7 mg, before reaching the maintenance dose of 2.4 mg. Each dose level uses a different pre-filled pen device. This gradual approach is specifically designed to reduce gastrointestinal side effects.
Serious adverse events reported at low rates in clinical trials included pancreatitis, gallbladder events (cholelithiasis), and injection site reactions. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A prescribing doctor will assess your full medical history before determining whether Wegovy is appropriate.
How Do You Get a Wegovy Prescription in Australia?
Any AHPRA-registered general practitioner in Australia can prescribe Wegovy. You do not need a specialist referral. A GP with appropriate clinical knowledge can assess your eligibility and issue a private prescription during a standard or telehealth consultation.
The process at Holistica Health involves three steps. First, you complete a pre-screening eligibility checklist online, which takes approximately two minutes. Second, you book a video consultation ($99 initial) with an AHPRA-registered GP who reviews your screening information, medical history, BMI, current medications, and treatment goals. Third, if clinically appropriate, the doctor writes a private prescription that you can fill at any Australian pharmacy.
The clinic operates seven days a week (9:00 AM to 7:00 PM AWST) and serves patients in every Australian state and territory. For patients considering their options, the Mounjaro vs Ozempic comparison guide provides a detailed side-by-side analysis of the main GLP1 medications available in Australia.
Once prescribed, Wegovy is stored between 2 and 8 degrees Celsius before first use (up to 28 days at room temperature after first use). It is administered as a subcutaneous injection once per week in the abdomen, thigh, or upper arm. Your pharmacist can demonstrate the correct injection technique.
Wegovy vs Mounjaro: Which Weight Loss Medication Should You Choose?
Both Wegovy and Mounjaro (tirzepatide) are TGA-approved for chronic weight management in Australia. The choice between them is a clinical decision that depends on your health profile, priorities, and cost considerations.
Weight loss magnitude: Tirzepatide (Mounjaro) has produced greater average weight loss in head-to-head trials: 20.2% vs 13.7% for semaglutide at maximum doses (SURMOUNT 5).
Cardiovascular evidence: Semaglutide (Wegovy) has published cardiovascular outcomes data from the SELECT trial showing a 20% MACE reduction. Tirzepatide’s cardiovascular trial (SURMOUNT MMO) is still underway. For patients with established heart disease, this is a significant clinical differentiator.
PBS pathway: Wegovy has an active PBAC recommendation for PBS listing. Mounjaro (tirzepatide) has had four unsuccessful PBS submissions for type 2 diabetes and no PBS recommendation for weight management.
Cost: Both are private prescriptions for weight loss. Wegovy’s maintenance dose costs approximately $200 to $460 per month. Mounjaro ranges from approximately $290 to $750 per month, depending on dose strength.
Your prescribing doctor can help you weigh these factors. For a full comparison, including Ozempic and Rybelsus, the Holistica Health GLP1 comparison page covers all four medications side by side.
Frequently Asked Questions
Is Wegovy the same as Ozempic?
Not exactly. Both contain semaglutide, but they are different products with different TGA-approved indications and different doses. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at a maintenance dose of 2.4 mg weekly. They use different pen devices and are not interchangeable. Your pharmacist cannot substitute one for the other.
When will Wegovy be on PBS in Australia?
The PBAC recommended Wegovy for PBS listing in January 2026, and Health Minister Mark Butler endorsed the recommendation. Price negotiations between the government and Novo Nordisk are ongoing. Based on standard timelines, a PBS listing could be finalized in late 2026 or early 2027, but no confirmed date has been announced. This page will be updated when the listing is confirmed.
Who will qualify for PBS-subsidized Wegovy?
The recommended PBS criteria are narrow: patients must have a BMI of 35 or higher (32.5 or higher for Asian, Aboriginal, and Torres Strait Islander populations) AND established cardiovascular disease, such as a prior heart attack, stroke, or symptomatic peripheral arterial disease. Most patients seeking weight loss treatment alone would not qualify under these initial criteria.
Do I need a specialist referral to get Wegovy?
No. Any AHPRA-registered general practitioner can prescribe Wegovy as a private prescription after a clinical assessment. You do not need a referral to an endocrinologist, bariatric physician, or any other specialist. Telehealth GPs can assess your eligibility and issue a prescription during a video consultation.
Can I switch from Ozempic to Wegovy?
Switching is possible, but must be managed by your prescribing doctor. Because Wegovy uses a higher maintenance dose (2.4 mg vs up to 2 mg for Ozempic), the transition requires careful dose adjustment. Your doctor may restart the Wegovy titration schedule depending on your current Ozempic dose and clinical response. Do not switch medications without medical supervision.
Is Wegovy on the PBS in Australia in 2026?
No. Wegovy is TGA approved for weight loss but is not yet listed on the PBS in Australia as of August 2026. The PBAC recommended a listing in November 2025 and the Health Minister endorsed it in January 2026, but price negotiations with Novo Nordisk are ongoing, with a possible listing in late 2026 or early 2027.
How much does Wegovy cost in Australia without PBS?
Without a PBS listing, patients pay the full private price for Wegovy, which varies by dose and pharmacy. Book a telehealth consultation with Holistica Health to confirm current pricing for the dose your doctor recommends and to check your eligibility for a prescription.
What to Do Next
Wegovy is the first GLP1 medication in Australia with both a TGA-approved weight management indication and published cardiovascular outcomes data showing a 20% reduction in major heart events. Its pathway to PBS subsidy is more advanced than any competing weight loss medication, though the initial eligibility criteria will be narrow.
For patients who do not meet the expected PBS criteria, Wegovy remains available as a private prescription through any AHPRA-registered GP. If you want to find out whether Wegovy or another GLP1 medication is right for you, complete the Holistica Health pre-screening eligibility checklist to book a telehealth consultation. The clinic also offers consultations for Mounjaro and Ozempic as part of a clinician-led weight loss program.